Navigation Links
National Pharmaceutical Council Comments on Patient-Centered Outcomes Research Institute Board of Governors
Date:9/23/2010

WASHINGTON, Sept. 23 /PRNewswire-USNewswire/ -- National Pharmaceutical Council (NPC) President Dan Leonard today commented on the appointment of the Board of Governors for the Patient-Centered Outcomes Research Institute (PCORI), a private, non-profit corporation created by the health reform law to develop and fund comparative effectiveness research (CER).  

"The decisions made by this first PCORI board will have a significant impact on the future of CER and its utility for health care decision makers," said Leonard. "After all, this board, along with the methodology committee, will be setting the framework for determining CER priorities, developing sound standards and methodologies for data and research, and translating research results in a useful and understandable way."

Leonard also outlined some general principles to ensure that CER will work to provide the best health outcomes for patients.

"Given the importance of the research that will be developed, the Board must ensure that there is a broad opportunity for discussion about CER findings by all key stakeholders who generate or disseminate this information," he said. He added that CER end users—health care decision makers who include patients, payers and physicians, among others—also will benefit from the harmonization of appropriate standards for CER generation because it will enable a more predictable environment for the adoption and use of evidence in decision-making.

"NPC applauds the Comptroller General for selecting a diverse and well qualified group of individuals to serve as PCORI's first board of governors," said Leonard. "We look forward to working with the members of PCORI as they prepare for the hard work that lies ahead."

NPC supported the creation of PCORI and outlined several principles for consideration in its testimony and comments before the federal agencies involved in the development of PCORI. NPC's previous comments on CER and rel
'/>"/>

SOURCE National Pharmaceutical Council
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. National Stem Cell Holding, Inc. Discovers Non-Embryonic Biomaterials that Promote Tissue Repair
3. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
4. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. Public Forum to Discuss Addiction as a Treatable Disease and Highlight National Alcohol and Drug Addiction Recovery Month
8. K-State Researchers Bringing Expertise to Kansas City Symposium on Disease and National Security
9. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
10. September is National Pain Awareness Month
11. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ... the "Dental Consumables Market - Global Industry ... - 2018" report to their offering. ... ) Dental consumables are products which are ... impairments, for tooth restoration and in treatment of ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading ... company, awarded several new IT value-added reseller (VAR) ... hospital organizations with IT goods and services at ... agreements, as well as value-added services such as ... New Novation agreements were awarded to ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 ... that it has waived the Office of Fair Trading (OFT) ... the outstanding shares of ViroPharma Incorporated (NASDAQ: VPHM).   ... no longer conditional on OFT approval, and Shire expects to ... currently scheduled expiration time, subject to the satisfaction of all ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Systems U.S.A., Inc. is pleased to announce the FDA ... Wireless. This new wireless version of the company,s ... quality in a lightweight design for enhanced versatility and ... imaging applications. The FDR D-EVO Wireless will be featured ...
... presented from pooled analyses of the STELARA® (ustekinumab) psoriasis ... STELARA and rates of adverse events remained consistent and ... plaque psoriasis receiving up to four years of treatment. ... placebo-controlled Phase 3 trials across patient populations on three ...
Cached Medicine Technology:FUJIFILM's FDR D-EVO™ Wireless Now Available in the U.S. 2New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 2New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 3New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 4New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 5New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 6New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 7New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 8New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 9New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 10New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 11
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... their effort to ensure,this generation of veterans is ... partnered with St. Johns, University School,of Risk Management, ... (IICF) on a three-day "Warriors to Work" Insurance,Industry ... wounded,warriors, most of whom were from the New ...
... is the best available option for people with hemochromatosis ... is often dismissed as a primitive form of medicine, ... of bad humors by draining the life-sustaining fluid. , ... is still the preferred means of treatment. , Hemochromatosis ...
... quality of care, communication and productivity,to new levels, while improving ... ... disciplines of care, PITTSBURGH, Aug. 25 Vocollect Healthcare ... retirement,community located in Wyomissing, Pennsylvania, will deploy AccuNurse(R),voice- assisted care ...
... Fitness tops competition on Inc. 5000 list ... rakes in revenue and new members, DOVER, N.H., ... for its "Judgment Free" atmosphere and friendly prices, earned,the ... 2008 list of,the 5,000 fastest-growing private businesses in the ...
... be racing faster this fall for every medical student in ... student and resident must pass will be delivered in a ... a skill that some say has become an Achilles heel ... doctors and residents out there taking this test know they ...
... and supplies to the EMS market, announced today the release of ... design first introduced to the EMS community in 1999. , ... ... [Hartwell Medical], a leading supplier of [emergency medical equipment] and ...
Cached Medicine News:Health News:Wounded Warrior Project (WWP), St. John's University, and Insurance Industry Charitable Foundation Partner to Assist Wounded Warriors 2Health News:For Rare Blood Disorder, Pumping Iron Is the Cure 2Health News:For Rare Blood Disorder, Pumping Iron Is the Cure 3Health News:The Highlands at Wyomissing Invests in Voice-Assisted Care to Take Excellence in Retirement Living to New Levels 2Health News:The Highlands at Wyomissing Invests in Voice-Assisted Care to Take Excellence in Retirement Living to New Levels 3Health News:N.H.-Based Health Club Operator Sets The Industry's Pace 2Health News:Listen up! 2Health News:Hartwell Medical Announces Release of CombiCarrierII Scoop Backboard to EMS Market 2Health News:Hartwell Medical Announces Release of CombiCarrierII Scoop Backboard to EMS Market 3
... Stratasis TF is a minimally ... treat stress urinary incontinence resulting from ... sphincter deficiency. The Stratasis TF Kit ... antegrade or retrograde placement. Supplied ...
... Used to dilate the ... medium to assess possible submucosal ... a topical anesthetic in the ... passage by, or dislodgment of ...
Used for drainage and retrograde pyelogram. Supplied sterile in peel-open packages. Intended for one-time use....
Used for drainage and navigation of a tortuous ureter. The tapered tip eases placement as there are no edges to interfere with the ureteral orifice. Supplied sterile in peel-open packages. Intended f...
Medicine Products: